Stayble Therapeutics AB appoints Jarkko Kalliomäki as Chief Medical Officer

Stayble Therapeutics AB (”Stayble” or ”the Company”) today announces that Jarkko Kalliomäki will assume the role of Chief Medical Officer (CMO) in the Company. Jarkko Kalliomäki is a specialist physician in rehabilitation and pain management and a medical doctor in physiology. He has over ten years of experience in the pharmaceutical industry in a number of pain-related projects and works as a senior physician in rehabilitation medicine and pain management at, among others, Lunds Universitetssjukhus Sophiahemmet and Capio S:t Göran's hospital, Stockholm.

"With Jarkko as CMO, Stayble gains an experienced pain physician who can support the execution of our clinical studies for both degenerative disc disease and chronic lumbar disc herniation as well as be an important resource in future partnership discussions. His broad experience as a consultant and specialist in the pain-related field will be very valuable to us," comments Stayble's CSO Anders Lehmann.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

E-mail: andreas.gerward@stayble.se

Phone: +46 (0) 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Advisor.